EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial
Value in Health · 2024-06 · 27 (6) · S65
DOI: 10.1016/j.jval.2024.03.347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2024-06. Verfasst von J Benner und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Benner, J., Li-McLeod, J., Bloomfield, D., & Ellis, A. (2024). EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial. Value in Health, 27(6), S65. https://doi.org/10.1016/j.jval.2024.03.347
Vancouver
Benner J, Li-McLeod J, Bloomfield D, Ellis A. EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial. Value in Health. 2024;27(6):S65. doi:10.1016/j.jval.2024.03.347
BibTeX
@article{Benner2024,
author = {Benner, J and Li-McLeod, J and Bloomfield, D and Ellis, A},
title = {EE46 An Early Cost-Effectiveness Analysis of Abelacimab Versus Rivaroxaban, a Standard of Care Direct Oral Anticoagulant (DOAC), in Patients with Atrial Fibrillation Using Preliminary Results from the AZALEA-TIMI 71 Trial},
journal = {Value in Health},
year = {2024},
volume = {27},
number = {6},
pages = {S65},
doi = {10.1016/j.jval.2024.03.347}
}
EUVIMED